1. Home
  2. ALMU vs MGNX Comparison

ALMU vs MGNX Comparison

Compare ALMU & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeluma Inc.

ALMU

Aeluma Inc.

HOLD

Current Price

$24.19

Market Cap

257.6M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.13

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALMU
MGNX
Founded
2019
2000
Country
United States
United States
Employees
14
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
257.6M
220.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
ALMU
MGNX
Price
$24.19
$4.13
Analyst Decision
Strong Buy
Buy
Analyst Count
3
5
Target Price
$24.67
$5.00
AVG Volume (30 Days)
1.1M
618.6K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
$17.49
N/A
Revenue Next Year
$60.61
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.24
$1.19
52 Week High
$31.79
$4.64

Technical Indicators

Market Signals
Indicator
ALMU
MGNX
Relative Strength Index (RSI) 51.00 55.58
Support Level $13.88 $1.49
Resistance Level $30.29 $4.55
Average True Range (ATR) 3.15 0.25
MACD -0.18 -0.04
Stochastic Oscillator 40.80 49.61

Price Performance

Historical Comparison
ALMU
MGNX

About ALMU Aeluma Inc.

Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: